drugset / Trial / NCT01120717

A Study to Assess the Long-term Safety of QVA149

NCT01120717

Phase 3 Completed 339 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2010-04
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown 50 ug Inhaled
Subject Indacaterol Other / unclassified 110 ug Inhaled